Agitated patients are often prescribed antipsychotic medications and sedatives off-label, but this can pose a risk to the ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

Jefferies Financial Group started coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report ...

President Trump’s newly announced tariff policy has done more than just push the stock markets deeper into correction territory — the sudden ...

Fintel reports that on April 7, 2025, Jefferies initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Buy ...

Jefferies initiated coverage of Axsome Therapeutics (AXSM) with a Buy rating and $200 price target The company currently markets three central ...

CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol ...

Axsome Therapeutics stock opened at $98.86 on Thursday. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $139.13. The company has a quick ratio of 2.04, a current ratio of 2. ...

NEW YORK - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a $5.26 billion market cap company specializing in central nervous system (CNS) disorder treatments, has announced positive trial results for ...

AXS-05 was well-tolerated and significantly delayed the time to agitation relapse compared with placebo in patients with ...

Forbes don release dia annual World Billionaires list. Overall, na 3,028 billionaires make di list dis year, dia combine ...